Global Clinical Microbiology Market - 2020-2027
発行: DataM Intelligence
Clinical microbiology focuses on all aspects of patient infections from testing samples to identifying bacterial, viral, fungal, and parasitic agents that are contributing to the infectious process, to determining the susceptibility of microorganisms to various antimicrobial agents, and reporting the results to healthcare providers.
The adaptation of microbiological techniques to the study of the etiological agents of infectious disease. Clinical microbiology determine the nature of infectious disease and test the ability of various antibiotics to inhibit or kill the isolated microorganisms. In addition to bacteriology, a contemporary clinical microbiologist is responsible for a wide range of microscopic and cultural studies in mycology, parasitology, and virology. The clinical microbiology is often the most competent person available to determine the nature and extent of hospital-acquired infections, as well as public-health problems that affect both the hospital and the community.
The market is driven is the rising infectious diseases are primarily diagnosed using clinical tests. According to the Centers for Disease Control and Prevention (CDC), around 9,421 new cases of tuberculosis, 51,455 new cases of salmonella, 33,461 new cases of Lyme disease, and 433 new cases of meningococcal disease were registered in U.S. in 2014.
Similarly, according to the American Cancer Society, around 1,688,780 new cases of cancer were diagnosed in U.S. in 2017. Thus, high prevalence of diseases where clinical tests are used as one of the major diagnostic tools is expected to augment market growth in future. Sudden outbreaks of Ebola, Zika, and other contagious pathogens are also contributing to rising prevalence of infectious diseases. As per an article published in the Journal of Clinical Microbiology, there is a shortage of trained and skilled professionals in medical and microbiological laboratories for processing and interpreting samples and specimens. Moreover, there has been a steep decline in the number of medical laboratory training programs and students graduating from such programs in U.S.
As high-income countries are stepping up their pursuit of countering hospital-acquired infections, middle- and low-income countries are recognizing the threat. Introduction of automated systems and innovative designs is expected to intensify market competition and change market dynamics over the forecast period. This factor is driving the growth of market in the forecast period.
The World Health Organization (WHO) is particularly active in countries such as Ethiopia, Burkina Faso, Nigeria, Algeria, and Senegal, where occurrence of HAIs ranged between 2.5% and 14.8%. This has led to increased demand for HAI diagnostics in these countries. Countries such as India, Sri Lanka, Pakistan, and Bhutan are also actively participating in HAI awareness programs. India and China are projected to be the main countries driving demand for HAI diagnostics instruments and tests in future. This factor is also driving the growth of market in the forecast period.
Similarly, factors like the consolidation of diagnostic laboratory chains and the increase in public awareness are driving the growth of the market. The emerging countries are expected to outperform the U.S. and European countries. This is mainly due to the increase in the major hospital chains opening new centers in major cities as well as an increase in the government expenditure.
However, Clinical microbiology testing procedures are not adequately reimbursed across a number of countries such as India, China, and other emerging countries in the Middle East and Africa, which have a high target patient population base. This is a major factor that limits the preference for clinical microbiology products among patients and healthcare professionals. This directly affects the adoption of premium-priced clinical microbiology products, thereby negatively affecting their market growth in the forecast period.
The recent outbreak of the COVID-19 pandemic is negatively affect the growth of the market as the laboratories are busy in the COVID-19 test which has halt all another test. This factor will hinder the growth of the market in the forecast period.
The global clinical microbiology market is segmented based on product type by laboratory instruments which is further sub segmented into incubators, gram strainers, bacterial colony counters, autoclave sterilizers, petri dish fillers and automated culture systems which is further sub segmented into microbiology analyzers, molecular diagnostic instruments, microscopes, mass spectrometers and reagents. The reagents segment held the largest market share. Factors such as higher cost of specialized kits and constant repeat purchase are expected to drive the segment over the forecast period. A reagent s a substance or compound added to a system to cause a chemical reaction, or added to test if a reaction occurs. The importance of reagents will continue to outstrip supplies in many places as the race for safe and effective vaccines and treatment. A reagent may be used to tell whether or not a specific chemical substance is present by causing a reaction to occur with it.
The laboratory instruments segment is expected to have positive market. Laboratories require a variety of equipment and consumables to perform tests and research activities. These are found in different types of laboratories such as research labs, clinical diagnostic labs, pathology lab, microbiology lab, educational labs, etc. to carry out research, scientific experiments and execute analyses of different scientific materials.
It is estimated that laboratory instrument segment is expected to witness significant growth over the forecast period, owing to technological advancements in the field of laboratory equipment, increase in number of clinical diagnostic procedures, and rise in private & public healthcare investments. In addition, favorable insurance policies related to laboratory equipment further supplement the market growth. Furthermore, increase in research related to life science and biotechnology boosts the laboratory instruments segment
Government and private research firms are taking initiatives in the research and development activities in context to diagnose and treat several disease worldwide through innovative technologies like specialty instruments. For instance, in 2016, Cancer Research UK spend US$ 583 million on cancer research to develop new treatment and to optimize existing cancer treatment. The amount spent was US$ 51 million on clinical trials study, US$ 50 million on research into new drugs and US$ 23 million on research to identify possible causes of cancer. This factor is further driving the growth of market.
Increasing chronic diseases such as chronic respiratory diseases, cardiovascular diseases and diabetes, and increasing incidence of lifestyle diseases such as heart disease, obesity, atherosclerosis and hereditary disease such as hemophilia, Down's syndrome, cystic fibrosis and sickle cell anemia are leading to the increasing demand of laboratory equipment to bring innovative technologies in the market. According to World Health Organization (WHO), non-communicable disease leads to cause 40 million deaths each year, which is equivalent to 70% of all deaths worldwide. Cardiovascular diseases account for most of NCD mortality (17.7 million) annually, followed by cancer (8.8 million), respiratory disease (3.9 million) and diabetes (1.6 million). Thus, these factor will drive the growth of the market in the forecast period.
Further, the market is also classified based on application as respiratory diseases, bloodstream infections, gastrointestinal diseases and others. The respiratory diseases segment is held the largest market share. Rise in prevalence of respiratory infectious diseases, such as Coronavirus diseases, MERS, chronic obstructive pulmonary disease, tuberculosis, pertussis, and influenza, is projected to drive the segment.
According to data published in January 2020, 2519 laboratory-conformed cases of Middle East respiratory syndrome (MERS), were reported, which includes 866 associated deaths globally. Majority of cases reported were from Saudi Arabia (2121 cases), including 788 related deaths with a higher fatality rate of 37.1%.
Moreover, the emergence of COVID 19 pandemic has driven the segment. According to statistics, as of April 2020, there were around 3.45 million cases of COVID-19 globally, which drives the respiratory diseases segment. This factor will drive the growth of the market in the forecast period.
By region, the global clinical microbiology market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global surgical glue market and is expected to grow at the highest CAGR during the forecast period due to an increase in burden of COVID-19, well-developed health care infrastructure, and increasing prevalence of chronic obstructive pulmonary diseases, flu diseases, whooping cough, and other respiratory infections. This is anticipated to augment the Respiratory infectious disease treatment market in the region. COPD is considered to be the third-leading cause of death in the U.S., and fourth-leading cause of death across the world. According to an article published on Very well Health, COPD affects around 11 million people in the U.S. and occurs in people over the age of 40. This statistics drives the demand for the treatment of respiratory infectious diseases. This factor will drive the growth of the market in the region.
Europe was the second-largest market for respiratory infectious diseases followed by Asia Pacific, owing to the rising prevalence of COPD disease in the region. For instance, according to the European Respiratory Nurses Association (ERNA), 259,000 people die of COPD each year in the EU. Moreover, rising cases of COVID 19 in Italy, Spain, U.K. and other countries across Europe is boosting the need for treatment of respiratory infectious diseases across the region.
The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, owing to the COVID-19 pandemic and key players involved in manufacturing generic drugs for the treatment of the disease. This factor will drive the growth of the market in the region.
The global clinical microbiology market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market bioMerieux SA, Danaher Corporation, Becton, Dickinson and Company, Abbott Laboratories, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche AG, Bruker Corporation, Hologic, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.
The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the clinical microbiology across the globe.
For instance, in 2017, bioMerieux held the leading position of the global clinical microbiology market. The company has a robust product portfolio and a strong geographical presence in more than 150 countries across the world. To maintain its leadership position in the market, the company has been focusing on R&D activities and new product launches.
In 2017, Hologic (US) collaborated with Seegene Inc. (South Korea) to develop and supply highly multiplexed real-time PCR reagents and assays for Hologic's Panther Fusion platform.
*The global clinical microbiology market report will provide access to approximately 38 market data tables, 52 figures, and 200 pages.